Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk

Dow Jones

10/27

0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. "We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma," the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com)

(END) Dow Jones Newswires

October 27, 2025 03:19 ET (07:19 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2578692206"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578692206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578692206?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578692206","market":"sg","top_or_hot":-1,"title":"Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 03:19 ET (07:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics Poised for Global Growth on Takeda Cancer Drug Partnership -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-27 15:19</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 27, 2025 03:19 ET (07:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0455707207.USD","symbol_name":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578692206","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578692206","pubTimestamp":1761549540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","HSHD.SI":"HSBC HK SDR 5to1","BK4207":"综合性银行","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","BK1610":"ETF&股票定投概念","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1601":"香港本地股","BK4585":"ETF&股票定投概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","00005":"汇丰控股","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","BK1583":"高瓴概念","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","HSBC":"汇丰","BK1231":"综合性银行","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01801":"信达生物","BK4521":"英国银行股","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1572":"香港银行股","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1589":"北水核心资产","BK4588":"碎股","HSBA.UK":"汇丰控股有限公司","03143":"华夏香港银行股"},"translate_title":"信达生物通过武田癌症药物合作伙伴关系实现全球增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00005":0.7,"01801":0.9,"03143":0.6,"HSBA.UK":0.6,"HSBC":0.9,"HSHD.SI":0.6},"content_text":"0719 GMT - Innovent's co-development and licensing partnership with Japan's Takeda on two new cancer drugs is expected to accelerate its globalization and unlock the treatments' overseas value, HSBC analysts Linda Shu and Cindy Chai say in a note. The deal should improve Innovent's overseas clinical execution and regulatory knowledge, while its U.S. co-sales model will help build sales capabilities and strengthen market access. Innovent's $2 billion cash position and expected profitability from 2025 should further support global expansion. \"We believe this deal should benefit Innovent's 2030 ambition to grow from a leading China biopharma to a global premier biopharma,\" the analysts add. HSBC views the stock as attractively valued, maintains a buy rating and raises its target price to HK$125.00 from HK$115.00. Shares were last at HK$86.00. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 03:19 ET (07:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}